The Indian Competition Authority approves a merger of two global pharmaceutical companies subject to divestitures in seven markets for different formulations (Sun Pharma / Ranbaxy)

Sun-Ranbaxy deal got conditional approval from CCI* CCI vide its order dated December 5, 2014 has conditionally approved the proposed merger between Sun Pharma and Ranbaxy (collectively called as “parties”), subject to the parties inter alia carrying out the divestiture of their products relating to seven relevant markets for formulations. This is the first time in the history of Indian Competition Law that CCI has ordered the sale of certain assets before approving a merger, wherein, parties have been directed to sell certain products before the merger can be made effective. After considering the response of both the parties to the show cause notice issued by CCI and the comments received from the members of the public on the proposed combination after the publication of details of

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

  • Vaish Associates Advocates (New Delhi)

Citation

Man Mohan Sharma, The Indian Competition Authority approves a merger of two global pharmaceutical companies subject to divestitures in seven markets for different formulations (Sun Pharma / Ranbaxy), 5 décembre 2014, e-Competitions December 2014, Art. N° 87209

Visites 83

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues